Tumor marker response to SARS‐CoV‐2 infection among patients with cancer
Abstract Background Inflammatory responses from benign conditions can cause non‐cancer‐related elevations in tumor markers. The severe acute respiratory coronavirus 2 (SARS‐CoV‐2) induces a distinct viral inflammatory response, resulting in coronavirus disease 2019 (COVID‐19). Clinical data suggest...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-07-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.4646 |
| _version_ | 1811290189054607360 |
|---|---|
| author | Alexander H. Gunn Carolyn Tashie Steven Wolf Jesse D. Troy Yousuf Zafar |
| author_facet | Alexander H. Gunn Carolyn Tashie Steven Wolf Jesse D. Troy Yousuf Zafar |
| author_sort | Alexander H. Gunn |
| collection | DOAJ |
| description | Abstract Background Inflammatory responses from benign conditions can cause non‐cancer‐related elevations in tumor markers. The severe acute respiratory coronavirus 2 (SARS‐CoV‐2) induces a distinct viral inflammatory response, resulting in coronavirus disease 2019 (COVID‐19). Clinical data suggest carcinoembryonic antigen (CEA), carbohydrate antigen 19–9 (CA 19–9), and cancer antigen 125 (CA 125) levels might rise in patients with COVID‐19. However, available data excludes cancer patients, so little is known about the effect of COVID‐19 on tumor markers among cancer patients. Methods We conducted a case series and identified patients with a positive SARS‐CoV‐2 PCR test, diagnosis of a solid tumor malignancy, and a CEA, CA 19–9, CA 125, or CA 27–29 laboratory test. Cancer patients with documented COVID‐19 infection and at least one pre‐ and two post‐infection tumor marker measurements were included. We abstracted the electronic health record for demographics, cancer diagnosis, treatment, evidence of cancer progression, date and severity of COVID‐19 infection, and tumor marker values. Results Seven patients were identified with a temporary elevation of tumor marker values during the post‐COVID‐19 period. Elevation in tumor marker occurred within 56 days of COVID‐19 infection for all patients. Tumor markers subsequently decreased at the second time point in the post‐infectious period among all patients. Conclusion We report temporary elevations of cancer tumor markers in the period surrounding COVID‐19 infection. To our knowledge this is the first report of this phenomenon in cancer patients and has implications for clinical management and future research. |
| first_indexed | 2024-04-13T04:08:34Z |
| format | Article |
| id | doaj.art-25f2c24b8421423fbbb1ce743ed38b98 |
| institution | Directory Open Access Journal |
| issn | 2045-7634 |
| language | English |
| last_indexed | 2024-04-13T04:08:34Z |
| publishDate | 2022-07-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj.art-25f2c24b8421423fbbb1ce743ed38b982022-12-22T03:03:09ZengWileyCancer Medicine2045-76342022-07-0111142865287210.1002/cam4.4646Tumor marker response to SARS‐CoV‐2 infection among patients with cancerAlexander H. Gunn0Carolyn Tashie1Steven Wolf2Jesse D. Troy3Yousuf Zafar4Duke University School of Medicine Durham North Carolina USADuke Cancer Institute Durham North Carolina USADepartment of Biostatistics and Bioinformatics Duke University Durham North Carolina USADepartment of Biostatistics and Bioinformatics Duke University Durham North Carolina USADuke University School of Medicine Durham North Carolina USAAbstract Background Inflammatory responses from benign conditions can cause non‐cancer‐related elevations in tumor markers. The severe acute respiratory coronavirus 2 (SARS‐CoV‐2) induces a distinct viral inflammatory response, resulting in coronavirus disease 2019 (COVID‐19). Clinical data suggest carcinoembryonic antigen (CEA), carbohydrate antigen 19–9 (CA 19–9), and cancer antigen 125 (CA 125) levels might rise in patients with COVID‐19. However, available data excludes cancer patients, so little is known about the effect of COVID‐19 on tumor markers among cancer patients. Methods We conducted a case series and identified patients with a positive SARS‐CoV‐2 PCR test, diagnosis of a solid tumor malignancy, and a CEA, CA 19–9, CA 125, or CA 27–29 laboratory test. Cancer patients with documented COVID‐19 infection and at least one pre‐ and two post‐infection tumor marker measurements were included. We abstracted the electronic health record for demographics, cancer diagnosis, treatment, evidence of cancer progression, date and severity of COVID‐19 infection, and tumor marker values. Results Seven patients were identified with a temporary elevation of tumor marker values during the post‐COVID‐19 period. Elevation in tumor marker occurred within 56 days of COVID‐19 infection for all patients. Tumor markers subsequently decreased at the second time point in the post‐infectious period among all patients. Conclusion We report temporary elevations of cancer tumor markers in the period surrounding COVID‐19 infection. To our knowledge this is the first report of this phenomenon in cancer patients and has implications for clinical management and future research.https://doi.org/10.1002/cam4.4646cancer managementclinical managementclinical observationsCOVID‐19tumor markersviral infection |
| spellingShingle | Alexander H. Gunn Carolyn Tashie Steven Wolf Jesse D. Troy Yousuf Zafar Tumor marker response to SARS‐CoV‐2 infection among patients with cancer Cancer Medicine cancer management clinical management clinical observations COVID‐19 tumor markers viral infection |
| title | Tumor marker response to SARS‐CoV‐2 infection among patients with cancer |
| title_full | Tumor marker response to SARS‐CoV‐2 infection among patients with cancer |
| title_fullStr | Tumor marker response to SARS‐CoV‐2 infection among patients with cancer |
| title_full_unstemmed | Tumor marker response to SARS‐CoV‐2 infection among patients with cancer |
| title_short | Tumor marker response to SARS‐CoV‐2 infection among patients with cancer |
| title_sort | tumor marker response to sars cov 2 infection among patients with cancer |
| topic | cancer management clinical management clinical observations COVID‐19 tumor markers viral infection |
| url | https://doi.org/10.1002/cam4.4646 |
| work_keys_str_mv | AT alexanderhgunn tumormarkerresponsetosarscov2infectionamongpatientswithcancer AT carolyntashie tumormarkerresponsetosarscov2infectionamongpatientswithcancer AT stevenwolf tumormarkerresponsetosarscov2infectionamongpatientswithcancer AT jessedtroy tumormarkerresponsetosarscov2infectionamongpatientswithcancer AT yousufzafar tumormarkerresponsetosarscov2infectionamongpatientswithcancer |